Shield Therapeutics PLC
LSE:STX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shield Therapeutics PLC
Total Current Liabilities
Shield Therapeutics PLC
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shield Therapeutics PLC
LSE:STX
|
Total Current Liabilities
£50.2m
|
CAGR 3-Years
58%
|
CAGR 5-Years
86%
|
CAGR 10-Years
30%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Total Current Liabilities
£21.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Total Current Liabilities
$30.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Total Current Liabilities
$1.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Total Current Liabilities
£27.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Total Current Liabilities
£36.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
Shield Therapeutics PLC
Glance View
Shield Therapeutics Plc is a pharmaceutical company. The company is headquartered in Gateshead, Tyne And Wear and currently employs 16 full-time employees. The company went IPO on 2016-02-26. The firm specializes in the development and commercialization of late-stage pharmaceuticals which address areas of unmet medical need. The firm's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. Its pipeline product candidate, PT20, is an iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia related to dialysis or non-dialysis dependent chronic kidney disease (CKD). PT20 has completed its Phase II pivotal study. Its subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (UK) Limited, Phosphate Therapeutics Limited, and others.
See Also
What is Shield Therapeutics PLC's Total Current Liabilities?
Total Current Liabilities
50.2m
GBP
Based on the financial report for Dec 31, 2025, Shield Therapeutics PLC's Total Current Liabilities amounts to 50.2m GBP.
What is Shield Therapeutics PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
30%
Over the last year, the Total Current Liabilities growth was 54%. The average annual Total Current Liabilities growth rates for Shield Therapeutics PLC have been 58% over the past three years , 86% over the past five years , and 30% over the past ten years .
